Efficacy of CRISPR-Based Gene Editing in a Sickle Cell Disease Patient as Measured through the Eye

Table 1

Serologies before and after gene editing.

Serology	Before gene editing	After gene editing	Normal range
Hb	7.7–9.6 g/dL	13.3 g/dL	13.9–16.3 g/dL
% Hb A	45%	0.00%	N/A
% Hb S	70–80%	50%	N/A
% Hb F	1.9%	45%	N/A
Hct	23–27.5%	36%	42.0–52.0%
MCV	88.7–109.2 FL	95.7 FL	80.0–98.0 FL
RDW	22.9–24.1%	15%	11.5–15.0%
Indirect bilirubin	2.7–8.1 mg/dL	3.3 mg/dL	0.2–0.8 mg/dL
Reticulocytes	7.0–10.2%	4.70%	0.7–2.8%

Hb, hemoglobin; %, percent; Hct, hematocrit; MCV, mean corpuscular volume; RDW, red blood cell distribution width; , grams; dL, deciliter; N/A, nonapplicable; FL, femtoliter; mg, milligram.